Reviewer’s report

Title: A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab

Version: 1 Date: 07 Feb 2018

Reviewer: Keiko Wakahara

Reviewer's report:
The case report regarding ABPA treated with mepolizumab is interesting and useful information for clinicians.

I have three comments.
1. Authors used "forced expiratory volume in 1 second (FEV1)/FEV" many times in the manuscript. Do they mean "forced expiratory volume in 1 second (FEV1)/FVC"? Please check them.
2. Authors did not use Omalizumab for this patient because of the high level of total IgE. Did mepolizumab reduce total IgE level of this patient?
3. As authors mentioned, the report of ABPA treated with mepolizumab alone is not found yet. However, the report of ABPA treated with omalizumab and mepolizumab was published in J Allergy Clin Immunol Pract. 2017, 5(4): 1137. Can you comment about it?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?

If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**

Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal